Despite its efforts, the FDA Nanotechnology Task Force faces several challenges, including: - Rapidly evolving nanotechnology advancements that outpace regulatory frameworks. - Limited long-term data on the effects of nanomaterials. - Balancing the need for thorough risk assessment with the desire to promote innovation. - Coordinating with international regulatory agencies to ensure consistent standards.
